Related Experiment Video
Updated: Jul 11, 2026
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders
1Division of Hematology, Department of Medicine, Brigham and Women's Hospital, USA.
Purpose Of Review:
The identification and characterization of somatic disease alleles have greatly improved our understanding of the molecular pathogenesis of myeloproliferative disorders. This review focuses on recent studies investigating the role of activated tyrosine kinase signaling in the Philadelphia chromosome negative myeloproliferative disorders.
Recent Findings:
Previously identified tyrosine kinase mutations in chronic myeloid leukemia and other myeloproliferative disorders suggested the possibility that polycythemia vera, essential thrombocythemia and primary myelofibrosis are also caused by activated tyrosine kinases. Recent studies identified an activating mutation in the JAK2 tyrosine kinase (JAK2V617F) in most patients with polycythemia vera and in approximately half of those with essential thrombocythemia and primary myelofibrosis. More recently, activating mutations in the thrombopoietin receptor and in JAK2 exon 12 have been identified in JAK2V617F negative myeloproliferative disorders.
Summary:
The discovery of activated tyrosine kinases in the majority of patients with polycythemia vera, essential thrombocythemia and primary myelofibrosis has diagnostic and pathogenetic implications. Subsequent studies are needed to elucidate the cause of myeloproliferative disorders without known disease alleles and to determine if inhibition of JAK2 signaling has therapeutic efficacy in the treatment of polycythemia vera, essential thrombocythemia and primary myelofibrosis.
Insights
Activating mutations in tyrosine kinases, like JAK2V617F, are key drivers of myeloproliferative disorders. Further research is needed to understand causes and explore JAK2 inhibition as a therapy.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Somatic disease alleles improve understanding of myeloproliferative disorders (MPDs).
- Focus on activated tyrosine kinase signaling in Philadelphia chromosome-negative MPDs.
Purpose of the Study:
- Review recent studies on tyrosine kinase signaling in MPDs.
- Investigate the role of specific mutations in MPD pathogenesis.
Main Methods:
- Review of recent scientific literature.
- Analysis of identified mutations in tyrosine kinases and receptors.
Main Results:
- JAK2V617F mutation found in most polycythemia vera and half of essential thrombocythemia/primary myelofibrosis patients.
- Activating mutations in thrombopoietin receptor and JAK2 exon 12 identified in JAK2V617F-negative MPDs.
Conclusions:
- Activated tyrosine kinases have diagnostic and pathogenetic implications for MPDs.
- Further studies required for MPDs without known mutations and JAK2 inhibition efficacy.
